ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”),
an advanced materials company dedicated to the development of
technology and processes for the production of isotopes for use in
multiple industries, today announced the appointment of Heather
Kiessling as its chief financial officer (CFO), effective as of
July 1, 2024 (or such earlier date as may be mutually agreed), to
support the Company’s next pivotal phase of growth. Robert Ainscow,
who currently serves as the Company’s CFO and chief operating
officer (COO), will continue to serve as the Company’s COO,
enabling him to focus his full time and attention on the Company’s
operations and strategic initiatives.
“We have been laser-focused on cost management
since the Company’s inception and have outsourced many roles. As
the Company progresses from being a pre-commercial company to a
Company generating revenues, we require greater financial
infrastructure,” said Paul Mann, Executive Chairman and Chief
Executive Officer of ASP Isotopes.
“We are thrilled to welcome Ms Kiessling as our
new CFO,” added Robert Ainscow, CFO and COO. “Her expertise in
financial controls and experience as an operational CFO with a
track record of successful implementation of strategic plans in
corporate operations across several functional areas, such as human
resources, finance and accounting, research and development,
manufacturing, quality, sales and marketing departments, ideally
complement our executive management team.”
Ms. Kiessling has joined the Company from
Danforth Advisors LLC, a life science financial strategy
consultancy, where she has been providing consulting and advisory
services to ASP Isotopes since November 2021. Prior to joining
Danforth Advisors, Ms. Kiessling held finance leadership roles at
Cytonome/ST, LLC and AutoImmune Inc. Ms. Kiessling is a CPA and
holds a B.A. in management science from University of California,
San Diego, and an M.B.A. from University of Michigan Graduate
School of Business.
“I am excited to join ASP Isotopes during this
important stage of corporate growth, commercialization and
considerable progress in R&D. It represents a unique and
exciting opportunity given the Company’s important goals of
delivering enriched isotopes for the nuclear medicine, green
nuclear energy and semiconductor industries,” added Ms.
Kiessling.
Inducement Grants
In connection with her appointment, effective as
of her employment start date, the Company granted Ms. Kiessling
400,000 shares of the Company’s common stock. Subject to Ms.
Kiessling being continuously employed by the Company through each
applicable vesting date, the shares will vest in eight equal
instalments over four years, with 50,000 shares vesting on each of
the six-month anniversaries of Ms. Kiessling’s employment
start date. This restricted stock award was approved by the
Company’s Compensation Committee and Board of Directors and granted
under the Company’s 2024 Inducement Equity Incentive Plan as an
inducement material to Ms. Kiessling entering into employment with
ASP Isotopes, in accordance with Nasdaq Listing Rule 5635(c)(4).
The Company is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage
advanced materials company dedicated to the development of
technology and processes to produce isotopes for use in multiple
industries. The Company employs proprietary technology, the
Aerodynamic Separation Process (“ASP technology”). The Company’s
initial focus is on producing and commercializing highly enriched
isotopes for the healthcare and technology industries. The Company
also plans to enrich isotopes for the nuclear energy sector using
Quantum Enrichment technology that the Company is developing. The
Company has isotope enrichment facilities in Pretoria, South
Africa, dedicated to the enrichment of isotopes of elements with a
low atomic mass (light isotopes).
There is a growing demand for isotopes such as
Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and
Nickel-64 for new, emerging healthcare applications, as well as
Chlorine-37, Lithium-6, and Uranium-235 for green energy
applications. We believe the ASP technology (Aerodynamic Separation
Process) is ideal for enriching low and heavy atomic mass
molecules. For more information, please
visit www.aspisotopes.com.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy, and other future
conditions. Forward-looking statements can be identified by words
such as “believes,” “plans,” “anticipates,” “expects,” “estimates,”
“projects,” “will,” “may,” “might,” and words of a similar nature.
Examples of forward-looking statements include, among others but
are not limited to, statements we make regarding expected operating
results, such as future revenues and prospects from the potential
commercialization of isotopes, future performance under contracts,
and our strategies for product development, engaging with potential
customers, market position, and financial results. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks, and changes in circumstances that
are difficult to predict, many of which are outside our control.
Our actual results, financial condition, and events may differ
materially from those indicated in the forward-looking statements
based upon a number of factors. Forward-looking statements are not
a guarantee of future performance or developments. You are strongly
cautioned that reliance on any forward-looking statements involves
known and unknown risks and uncertainties. Therefore, you should
not rely on any of these forward-looking statements. There are many
important factors that could cause our actual results and financial
condition to differ materially from those indicated in the
forward-looking statements, including, but not limited to, our
future capital requirements and sources and uses of cash; our
ability to obtain funding for our operations and future growth; our
reliance on the efforts of third parties; our ability to complete
the construction and commissioning of our enrichment plants or to
commercialize isotopes using the ASP technology or the Quantum
Enrichment Process; our ability to obtain regulatory approvals for
the production and distribution of isotopes; the financial terms of
any current and future commercial arrangements; our ability to
complete certain transactions and realize anticipated benefits from
acquisitions; contracts, dependence on our Intellectual Property
(IP) rights, certain IP rights of third parties; and the
competitive nature of our industry. Any forward-looking statement
made by us in this press release is based only on information
currently available to us and speaks only as of the date on which
it is made. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise. This press release includes
market and industry data and forecasts that we obtained from
internal research, publicly available information and industry
publications and surveys. Industry publications and surveys
generally state that the information contained therein has been
obtained from sources believed to be reliable. Unless otherwise
noted, statements as to our potential market position relative to
other companies are approximated and based on third-party data and
internal analysis and estimates as of the date of this press
release. We have not independently verified this information, and
it could prove inaccurate. Industry and market data could be wrong
because of the method by which sources obtained their data and
because information cannot always be verified with certainty due to
the limits on the availability and reliability of raw data, the
voluntary nature of the data-gathering process and other
limitations and uncertainties. In addition, we do not know all of
the assumptions regarding general economic conditions or growth
that were used in preparing the information and forecasts from
sources cited herein. No information in this press release should
be interpreted as an indication of future success, revenues,
results of operation, or stock price. All forward-looking
statements herein are qualified by reference to the cautionary
statements set forth herein and should not be relied upon.
Contacts
Jason Assad– Investor
relationsEmail: Jassad@aspisotopes.comTelephone:
561-709-3043
ASP Isotopes (NASDAQ:ASPI)
Historical Stock Chart
From May 2024 to Jun 2024
ASP Isotopes (NASDAQ:ASPI)
Historical Stock Chart
From Jun 2023 to Jun 2024